Seroprevalence of cytomegalovirus infection
in the United States, 1988-1994.
Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection
Other common causes include exposure to excessive noise, injuries to the ear or head, ageing, genetic causes, problems during pregnancy and childbirth (such as cytomegalovirus infection
or syphilis) and the use of medications that can damage hearing.
Definitions of cytomegalovirus infection
and disease in transplant recipients.
The viral association of neonatal cholestasis in Sweden: a possible link between cytomegalovirus infection
and extrahepatic biliary atresia.
Swabbing a newborn's mouth for saliva can be used to quickly and effectively screen for cytomegalovirus infection
, or CMV, which is a leading cause of hearing loss in children.
in a day care center in the municipality of Sao Paulo.
Although cytomegalovirus infection
is a known cause of birth defects, including permanent hearing loss, most CMV infections in infants are not identified early.
The 18 chapters cover the following diseases and pathogens: influenza in 2009, human adenovirus 14, Acanthamoeba polyphaga mimivirus as a cause of pneumonia, hepatitis E, lymphocytic choriomeningitis virus-like arenavirus infections, human T-lymphotropic virus type 1 infections in indigenous populations, cytomegalovirus infection
after transplantation, malignancies and HIV infection, Arcobacter sp.
Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection
in coronary atheroma formation.
An international group of specialists in infectious diseases discuss newly recognized diseases, previously known pathogens that present new challenges, and domestic and international threats, including the 2009 flu pandemic in Australia, the reemergence of human adenovirus 14, acanthanmoeba polyphaga mimivirus, the global impact of hepatitis E, human T-lymphotropic virus 1 in indigenous populations in Australia, cytomegalovirus infection
in transplant recipients, HIV-associated malignancies, the global spread of multidrug-resistant gram-negative bacilli, sepsis in sub-Saharan Africa, neglected tropical diseases, infections in long-term care facilities and mobile populations, infectious plant diseases, and the One World-One Health initiative.
Cellestis Limited, a listed Australian biotechnology company founded in 2000 in Melbourne, Australia, develops and manufactures the QuantiFERON-CMV test, a breakthrough blood test for monitoring cytomegalovirus infection
and disease, and the QuantiFERON-TB Gold In-Tube (QFT(R)) test for tuberculosis infection.